SNU-449細(xì)胞
ATCC Number： CRL-2234?
相關(guān)**： 肝癌
器官來(lái)源： 肝
運(yùn)輸方式： 凍存運(yùn)輸
年限： grade II-III/IV
生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)
細(xì)胞形態(tài)： 其他
是否是腫瘤細(xì)胞： 1
物種來(lái)源： 人
數(shù)量： 大量
Designations: SNU-449
SNU-449細(xì)胞Depositors: J Park
Biosafety Level: 2 [CELLS CONTAIN HEPATITIS B VIRUS ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens
Morphology: epithelial; diffusely spreading cells
Source: Organ: liver
Tumor Stage: grade II-III/IV
Disease: hepatocellular carcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: SNU-449細(xì)胞This line is available under the following restrictions: 1.) The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.) Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. Telephone (02) 760-3380, Fax (02) 742-4727. 3.) In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication (Int. J. Cancer 62:276-282, 1995).
Isolation: Isolation date: 1990
Cytogenetic Analysis: aneuploid; modal number = 57
Age: 52 years
Gender: male
Ethnicity: Asian
Comments: SNU-449 was derived in 1990 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient prior to cytotoxic therapy.
Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat inactivated fetal bovine serum.
After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum.
Grossly, the original tumor was single nodular with perinodular extensions.
SNU-449細(xì)胞Histologically, it was predominantly compact and minor trabecular type.
The cultured cells contain a single or double nucleus.
Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.
HBV genomic RNA was not expressed.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:5 to 1:10 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: SNU-449細(xì)胞Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 36 hrs
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
References: 22872: Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080
